Cost-effectiveness of smoking cessation to prevent age-related macular degeneration.
BACKGROUND
Tobacco smoking is a risk factor for age-related macular degeneration, but studies of ex-smokers suggest quitting can reduce the risk.


METHODS
We fitted a function predicting the decline in risk of macular degeneration after quitting to data from 7 studies involving 1,488 patients. We assessed the cost-effectiveness of smoking cessation in terms of its impact on macular degeneration-related outcomes for 1,000 randomly selected U.S. smokers. We used a computer simulation model to predict the incidence of macular degeneration and blindness, the number of quality-adjusted life-years (QALYs), and direct costs (in 2004 U.S. dollars) until age 85 years. Cost-effectiveness ratios were based on the cost of the Massachusetts Tobacco Control Program. Costs and QALYs were discounted at 3% per year.


RESULTS
If 1,000 smokers quit, our model predicted 48 fewer cases of macular degeneration, 12 fewer cases of blindness, and a gain of 1,600 QALYs. Macular degeneration-related costs would decrease by $2.5 million if the costs of caregivers for people with vision loss were included, or by $1.1 million if caregiver costs were excluded. At a cost of $1,400 per quitter, smoking cessation was cost-saving when caregiver costs were included, and cost about $200 per QALY gained when caregiver costs were excluded. Sensitivity analyses had a negligible impact. The cost per quitter would have to exceed $77,000 for the cost per QALY for smoking cessation to reach $50,000, a threshold above which interventions are sometimes viewed as not cost-effective.


CONCLUSIONS
Smoking cessation is unequivocally cost-effective in terms of its impact on age-related macular degeneration outcomes alone.
Hurley
Susan F
SF
Bainbridge Consultants, 222/299 Queen St, Melbourne, VIC 3000, Australia. susanhurley@bainbridgeconsultants.com
Matthews
Jane P
JP
Guymer
Robyn H
RH
Med Decis Making. 2005 Jul-Aug;25(4):437-48
16061896
Arch Ophthalmol. 2001 Oct;119(10):1455-62
11594944
Am J Public Health. 2002 Jun;92(6):990-6
12036794
Ophthalmology. 2001 Apr;108(4):697-704
11297486
BMJ. 2000 Aug 5;321(7257):351-4
10926595
Tob Control. 2008 Dec;17(6):379-84
18719075
JAMA. 1996 Oct 9;276(14):1147-51
8827967
Am J Public Health. 2005 Jun;95(6):969-75
15914818
Br J Ophthalmol. 2006 Jan;90(1):75-80
16361672
Natl Vital Stat Rep. 2007 Aug 21;55(19):1-119
17867520
Arch Ophthalmol. 2000 Jan;118(1):47-51
10636413
Arch Ophthalmol. 1996 Oct;114(10):1193-6
8859077
BMJ. 2004 Apr 17;328(7445):947-9
15087348
Health Care Financ Rev. 2006 Spring;27(3):37-47
17290647
Cost Eff Resour Alloc. 2007 Jan 23;5:2
17241477
Am J Prev Med. 2001 Feb;20(2 Suppl):16-66
11173215
Cost Eff Resour Alloc. 2008 Jun 24;6:12
18573218
Pharmacoeconomics. 1997 Jun;11(6):538-49
10168094
Ophthalmology. 1997 Jan;104(1):7-21
9022098
Clin Exp Ophthalmol. 2006 Jan-Feb;34(1):6-8
16451251
Ophthalmic Epidemiol. 2004 Dec;11(5):359-67
15590583
N Engl J Med. 2006 Oct 5;355(14):1409-12
17021315
Ophthalmology. 2004 Jul;111(7):1280-7
15234127
JAMA. 1996 Oct 9;276(14):1141-6
8827966
N Engl J Med. 2006 Oct 5;355(14):1493-5
17021326
Arch Ophthalmol. 1998 Aug;116(8):1031-5
9715683
Nicotine Tob Res. 2002 Aug;4(3):311-9
12215240
Br J Ophthalmol. 2005 May;89(5):550-3
15834082
Eye (Lond). 2005 Sep;19(9):935-44
16151432